Adjuvant activity of CpG oligodeoxynucleotides.
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs directly stimulate human B cells and plasmacytoid dendritic cells (pDCs), thereby promoting the production of Th1 and proinflammatory cytokines and the maturation/activation of professional antigen-presenting cells. These activities enable CpG ODNs to act as immune adjuvants, accelerating and boosting antigen-specific immune responses by 5- to 500-fold. The CpG motifs present in bacterial DNA plasmids may contribute to the immunogenicity of DNA vaccines. Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans and can improve vaccine-induced immune responses.
Klinman
Dennis M
DM
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland, USA. klinman@cber.fda.gov
D000276:Adjuvants, Immunologic / Q000235:genetics / Q000494:pharmacology*; D000818:Animals; D018899:CpG Islands / Q000235:genetics / Q000276:immunology*; D006801:Humans; D051379:Mice; D009841:Oligonucleotides / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D012449:Safety / Q000592:standards; D014612:Vaccines / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D009841:Oligonucleotides; D014612:Vaccines; D019444:Vaccines, DNA